Multi-walled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics

H. Ali-Boucetta*, K. T. Al-Jamal, K. Kostarelos

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The potential of carbon nanotubes as carriers and delivery vectors for anticancer drugs was investigated. Herein, we propose MWNT-doxorubicin supramolecular complexes that can be developed for cancer therapy. The formation of such complexes is evidenced by a sharp decrease in the intensity of the doxorubicin fluorescence spectrum and takes place via π-π interactions with the MWNT backbone. In addition, the structural characteristics of the CNT-doxorubicin complexes were examined by transmission electron microscopy and showed well dispersed pluronic wrapped MWNT but clustered MWNT-doxorubicin structures. Very interestingly the doxorubicinMWNT complexes exhibit enhanced cytotoxic activity compared to both doxorubicin alone and doxorubicin-pluronic complexes.

Original languageEnglish
Title of host publicationTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Pages16-18
Number of pages3
Publication statusPublished - 2008
Event2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008 - Quebec City, QC, United States
Duration: 1 Jun 20085 Jun 2008

Publication series

NameTechnical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, NSTI-Nanotech, Nanotechnology 2008
Volume2

Conference

Conference2008 NSTI Nanotechnology Conference and Trade Show, NSTI Nanotech 2008 Joint Meeting, Nanotechnology 2008
Country/TerritoryUnited States
CityQuebec City, QC
Period1/06/085/06/08

Keywords

  • Cancer
  • Carbon nanotubes
  • Doxorubicin
  • Supramolecular complexes

ASJC Scopus subject areas

  • Mechanical Engineering

Fingerprint

Dive into the research topics of 'Multi-walled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics'. Together they form a unique fingerprint.

Cite this